Breaking News

Ono Pharmaceutical to Acquire Deciphera for $2.4B

Will enable ONO to build a robust presence in oncology, one of its key priority areas.

Author Image

By: Charlie Sternberg

Associate Editor

Deciphera Pharmaceuticals LLC., a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer, has entered into a definitive merger agreement with Ono Pharmaceutical Company, Ltd. (ONO) under which ONO will acquire all outstanding shares of Deciphera common stock in cash through a tender offer followed by a merger of Deciphera with a wholly-owned subsidiary of ONO, for a total equity value of $2.4 billion.   The boa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters